Results from the NRG Oncology GOG-0263 Phase III clinical trial testing the addition of cisplatin-based chemotherapy to ...

The addition of concurrent cisplatin chemotherapy to adjuvant radiation therapy (CRT), versus RT alone, couldn't move the ...

Results from the NRG Oncology GOG-0263 phase III clinical trial testing the addition of cisplatin-based chemotherapy to ...

Nanobiotix (NBTX) announced the execution of another step in its financial strategy through the amendment of the company’s global licensing ...

Cisplatin is one of the most widely used agents in the treatment of solid tumors, but its clinical utility is limited by toxicity. The development of less toxic, liposomal formulations of ...

Adjuvant CRT did not improve outcomes over adjuvant RT in patients with intermediate-risk, early-stage cervical cancer after radical hysterectomy.

The reference arm of paciltaxel and cisplatin for the Monk et al. 3 trial was selected on the basis of results from a GOG randomized phase III study, which demonstrated an improvement in objective ...

Sensorion Announces the End of Patient Inclusion in NOTOXIS Phase 2a Clinical Trial of SENS-401 for the Prevention of Cisplatin-Induced Ototoxicity ...

Chinese scientists have developed a new treatment for nasopharyngeal carcinoma that helps patients live longer and have a ...

The second group received no neoadjuvant therapy prior to surgery, followed by either standard of care radiotherapy with cisplatin (100mg/m 2 IV Q3W for 3 cycles) as adjuvant therapy following ...

An expert discusses how adjuvant therapy options for high-risk muscle-invasive bladder cancer (MIBC); ypT2-ypT4a or N+) ...

The NOTOXIS trial (ClinicalTrials.gov ID: NCT05628233) evaluates the efficacy of SENS-401 in preventing CIO in adult patients with neoplastic disease, four weeks after completion of cisplatin ...